Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phibro Animal Health Corporation (Nasdaq: PAHC) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Phibro’s animal health, mineral nutrition, and performance products businesses, as well as its governance, capital structure, and risk disclosures.
Key documents for PAHC include annual reports on Form 10-K and quarterly reports on Form 10-Q, where Phibro presents audited and interim financial statements, segment information for Animal Health, Mineral Nutrition, and Performance Products, and management’s discussion of factors affecting net sales, gross profit, operating expenses, and tax rates. These reports also describe product categories such as medicated feed additives, nutritional specialty products, vaccines, mineral nutrition products, and performance products.
Current reports on Form 8-K are particularly useful for tracking material events. For Phibro, recent 8-K filings have covered quarterly and annual financial results, updates to financial guidance, dividend declarations on Class A and Class B common stock, and a planned leadership transition in which Jack C. Bendheim is expected to move to an Executive Chairman role and Daniel (Dani) Bendheim is expected to become Chief Executive Officer and President as of a specified effective date. Other 8-K items document stockholder meeting results, including votes on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
Phibro’s definitive proxy statement (DEF 14A) provides extensive detail on corporate governance, Board structure, executive compensation philosophy and programs, related party transactions, and security ownership of certain beneficial owners and management. It also explains the voting rights of Class A and Class B common stock and the matters presented at the annual meeting.
On Stock Titan, AI-powered tools can help summarize lengthy filings such as 10-Ks, 10-Qs, 8-Ks, and proxy statements for PAHC, highlighting segment performance, notable risk or governance disclosures, and key decisions by the Board and stockholders. Users can also review filings related to dividends and other corporate actions, and, where available, monitor insider and beneficial ownership information reported in SEC forms. Real-time updates from EDGAR ensure that new Phibro filings appear promptly, while AI-generated overviews make it easier to understand the implications of complex regulatory documents.
Phibro Animal Health CorpBFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A common stock in open-market transactions from February 24–26, 2026, under a pre-established Rule 10b5-1 trading plan adopted on May 30, 2025.
The reported weighted-average sale prices for these trades were around $51–$54 per share, and the filing notes that some shares are held directly by Jack Bendheim while others are held indirectly through BFI Co., LLC.
BFI Co., LLC, an entity associated with Phibro Animal Health’s President and CEO Jack Bendheim, reported pre-planned open-market sales of 14,080 shares of Class A Common Stock under a Rule 10b5-1 trading plan. The weighted average sale prices were
After these indirect sales, BFI Co., LLC reported holding 22,600 shares, while Jack Bendheim directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health reported insider transactions involving an entity associated with its President and CEO, Jack Bendheim. BFI Co., LLC, a ten percent owner, sold a total of 14,080 shares of Class A Common Stock in open-market transactions on February 13 and 18, 2026 under a pre-established Rule 10b5-1 trading plan adopted on May 30, 2025. The weighted average sale prices were around $51–$52 per share, with detailed price ranges disclosed in the footnotes. After these sales, BFI held 36,680 shares, and Bendheim also directly held 16,840 shares. The filing notes that Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Phibro Animal Health insider activity shows that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 72,198 shares of Class A common stock in open-market transactions on February 10–11, 2026. The shares were sold under a pre-established Rule 10b5-1 trading plan adopted by BFI on May 30, 2025, at weighted average prices ranging from about $51.61 to $52.21. Following these indirect sales, BFI continued to hold 50,760 shares, while Bendheim directly held 16,840 shares.
David Glenn reported acquisition or exercise transactions in a Form 4 filing for PAHC. The filing lists transactions totaling 72,528 shares at a weighted average price of $51.63 per share. Following the reported transactions, holdings were 240,000 shares.
A shareholder of PAHC has filed a notice of proposed sale under Rule 144 for 12,528 Class A shares. The planned sale, through Fidelity Brokerage Services LLC on the NASDAQ, has an aggregate market value of $646,757.50 based on the figures provided.
The shares were acquired on 02/10/2026 via restricted stock vesting from the issuer as compensation, with payment on the same date. The filing notes that 20,623,682 shares of this class were outstanding and lists an approximate sale date of 02/11/2026.
Barclays PLC reported a passive ownership stake in Phibro Animal Health Corp-A common stock on a Schedule 13G. Barclays beneficially owns 1,042,888 shares, representing 5.10% of the class, with sole voting and sole dispositive power over all reported shares as of December 31, 2025.
Barclays states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Phibro Animal Health. Subsidiaries involved include Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.
Phibro Animal Health Corp’s insider filing shows activity on February 5, 2026 involving an entity associated with President and CEO Jack Bendheim. BFI Co., LLC converted 185,000 shares of Class B Common Stock into 185,000 shares of Class A Common Stock at an exercise price of $0.
BFI then executed several open-market sales of Class A shares under a Rule 10b5-1 trading plan, with individual trades ranging from 409 to 46,275 shares at weighted average prices between $44.4688 and $49.5718. After these transactions, BFI indirectly held 122,958 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health insider activity shows trades by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim and a 10% owner. On February 4, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A on a one-for-one basis at $0 per share.
BFI then sold Class A shares in several transactions: 6,689 shares at $41.2508, 2,971 shares at $41.9667, and 3,520 shares at $41.1544, all reported as weighted average prices under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these trades, BFI held 48,800 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares and BFI continued to hold additional Class B shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.
Phibro Animal Health Corporation filed a Form 8-K stating that on February 4, 2026 it issued a press release announcing operating results for the fiscal quarter ended December 31, 2025 and financial guidance for the fiscal year ending June 30, 2026. The press release is furnished as Exhibit 99.1 and, along with the 8-K disclosure, is designated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.